Investors

MolMed approves results at June 30th 2018, significantly improved compared to first half 2017. Zalmoxis update.
MolMed approves results at June 30th 2018, significantly improved compared to first half 2017. Zalmoxis update. ▾

Investors

MolMed signs a new, three-year agreement for the development and supply of lentiviral vectors MolMed will provide GSK with vectors for the oncology field
MolMed signs a new, three-year agreement for the development and supply of lentiviral vectors MolMed will provide GSK with vectors for the oncology field ▾

Investors

MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens
MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens ▾

Investors

MolMed and Orchard Therapeutics extend their collaboration in the field of gene therapy for rare diseases
MolMed and Orchard Therapeutics extend their collaboration in the field of gene therapy for rare diseases ▾

Investors

New and relevant data on the therapeutic potential of NGR-hTNF in brain lymphomas presented today at ASCO
New and relevant data on the therapeutic potential of NGR-hTNF in brain lymphomas presented today at ASCO ▾

News & Events

Stay update
Asco Annual Meeting ▾

Asco Annual Meeting

Location: McCormik Palace Chicago, IL

Investors

MolMed and Glycostem announce the execution of a binding termsheet for the development and manufacturing of allogeneic CAR-NK therapies
MolMed and Glycostem announce the execution of a binding termsheet for the development and manufacturing of allogeneic CAR-NK therapies ▾

Investors

Further data on the safety profile of CAR-T CD44v6 result from a study conducted by San Raffaele Hospital, published by the prestigious journal Nature Medicine
Further data on the safety profile of CAR-T CD44v6 result from a study conducted by San Raffaele Hospital, published by the prestigious journal Nature Medicine ▾